Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: Molecular mechanisms, penicillin-binding protein profiles, and binding affinities

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4771-4778

  Moyá, Bartolomé ^a,b   Beceiro, Alejandro ^c   Cabot, Gabriel ^a,b   Juan, Carlos ^a,b   Zamorano, Laura ^a,b   Alberti, Sebastián ^b   Oliver, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE AMPD; BETA LACTAMASE DACB; BETA LACTAMASE MEXB; BETA LACTAMASE MEXY; BETA LACTAMASE OPRD; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PENICILLIN BINDING PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HOSPITAL INFECTION; HUMAN; IC 50; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BINDING SITES; CARBAPENEMS; CEFTAZIDIME; CEPHALOSPORINS; CROSS INFECTION; GENE EXPRESSION; HUMANS; IMIPENEM; KINETICS; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; PROTEIN BINDING; PROTEIN ISOFORMS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84865413973     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00680-12     Document Type: Article

References (38)

1. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martínez JL. 2010. Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics. Antimicrob. Agents Chemother. 54:4159-4167.
2. Bratu S, Landman D, Gupta J, Quale J. 2007. Role of AmpD, OprF and penicillin-binding proteins in beta-lactam resistance in clinical isolates of Pseudomonas aeruginosa. J. Med. Microbiol. 56:809-814. (Pubitemid 46911237)
3. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559.
4. Cabot G, et al. 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob. Agents Chemother. 55:1906-1911.
5. Cavallo JD, Hocquet D, Plesiat P, Fabre R, Roussel-Delvallez M. 2007. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J. Antimicrob. Chemother. 59:1021-1024. (Pubitemid 47073379)
6. Cayô R, et al. 2011. Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 55:5907-5913.
7. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing, vol 28, no. 3, 18th informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
8. El Amin N, et al. 2005. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187-196. (Pubitemid 40524103)
9. Farra A, Islam S, Strålfors A, Sörberg M, Wretlind B. 2008. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents. 31:427-433.
10. Fernández-Cuenca F, et al. 2003. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:565-574. (Pubitemid 36336148)
11. Filip C, Fletcher G, Wulff JL, Earhart CF. 1973. Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate. J. Bacteriol. 115:717-722.
12. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54:3427-3431.
13. Giske CG, Buarø L, Sundsfjord A, Wretlind B. 2008. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microb. Drug Resist. 14:23-30. (Pubitemid 351441848)
14. Gutierrez O, et al. 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. 51:4329-4335. (Pubitemid 350209885)
15. Juan C, Moyá B, Pérez JL, Oliver A. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.
16. Juan C, et al. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54:846-851.
17. Juan C, et al. 2005. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738. (Pubitemid 41552606)
18. Lin CW, Lin HC, Huang YW, Chung TC, Yang TC. 2011. Inactivation of mrcA gene derepresses the basal-level expression of L1 and L2 β-lactamases in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 66:2033-2037.
19. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
20. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640. (Pubitemid 34165326)
21. Livermore DM, Mushtaq S, Ge Y, Warner M. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406.
22. Masuda N, et al. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327. (Pubitemid 33009490)
23. Mesaros N, et al. 2007. Pseudomonas aeruginosa: resistance and therapeutics options in the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578. (Pubitemid 46730662)
24. Moya B, et al. 2009. β-Lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 5:e1000353.
25. Moya B, et al. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
26. Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. 2010. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:3933-3937.
27. Mulet X, et al. 2011. Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob. Agents Chemother. 55:4560-4568.
28. Neuwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. 1995. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin binding proteins. J. Antimicrob. Chemother. 36:335-342.
29. Oh H, Stenhoff S, Jalal S, Wretlind B. 2003. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb. Drug Resist. 9:323-328. (Pubitemid 38168187)
30. Pirnay JP, et al. 2002. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4:872-882.
31. Poole K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26. (Pubitemid 38128588)
32. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2:65.
33. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
34. Riera E, et al. 2010. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J. Antimicrob. Chemother. 65:1399-1404.
35. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394.
36. Sumita Y, Fukasawa M. 1995. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3. J. Antimicrob. Chemother. 36:53-64.
37. Zapun A, Contreras-Martel C, Vernet T. 2008. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol. Rev. 32:361-385.
38. Zhao G, Meier T, Kahi SD, Gee KR, Blaszczak LC. 1999. Bocillin FL, a sensitive and commercially available reagent for the detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128. (Pubitemid 29214735)